Key facts
- It has raised $70.0M; the latest was Out of Business in Mar 2026.
- Status: Out of Business.
- ·Watchlist + deal alerts for TocopheRx
- ·The full record, as it builds
Funding rounds
No funding rounds for TocopheRx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TocopheRx
Developer of therapeutic medicines designed to treat reproductive infertility. The company's medicines combine the activity of both the male and female hormones, which are used to treat infertility, into a single molecule delivered in a tablet that could treat both men and women, enabling infertile couples to achieve their family plans effectively with less stress.
- Sector
- Healthcare
- HQ
- Burlington, MA, United States
- Founded
- 2013
- Employees
- 55
- Website
- tocopherx.com/
- Ownership
- Out of Business
TocopheRx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TocopheRx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TocopheRx in its N-PORT filings yet. We sweep new filings monthly.